372 Shares in Eli Lilly and Company $LLY Purchased by 21 West Wealth Management LLC

Key Points

• 21 West Wealth Management LLC purchased 372 shares of Eli Lilly and Company, valued at approximately $290,000, during the second quarter.
• A number of hedge funds increased their stakes in Eli Lilly, with Mirabaud & Cie SA boosting its holdings by 117.1%, now owning 12,345 shares worth $9,623,000.
• Eli Lilly recently declared a quarterly dividend of $1.50 per share, representing a $6.00 annualized dividend and a yield of 0.8%.

21 West Wealth Management LLC purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 372 shares of the company's stock, valued at approximately $290,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Apella Capital LLC boosted its holdings in shares of Eli Lilly and Company by 4.7% in the 2nd quarter. Apella Capital LLC now owns 1,831 shares of the company's stock worth $1,415,000 after buying an additional 82 shares during the last quarter. Bard Financial Services Inc. boosted its holdings in shares of Eli Lilly and Company by 1.4% in the 2nd quarter. Bard Financial Services Inc. now owns 2,815 shares of the company's stock worth $2,194,000 after buying an additional 40 shares during the last quarter. Legacy Private Trust Co. boosted its holdings in shares of Eli Lilly and Company by 5.0% in the 2nd quarter. Legacy Private Trust Co. now owns 10,769 shares of the company's stock worth $8,395,000 after buying an additional 512 shares during the last quarter. Mirabaud & Cie SA boosted its holdings in shares of Eli Lilly and Company by 117.1% in the 2nd quarter. Mirabaud & Cie SA now owns 12,345 shares of the company's stock worth $9,623,000 after buying an additional 6,658 shares during the last quarter. Finally, Gallacher Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 66.2% in the 2nd quarter. Gallacher Capital Management LLC now owns 796 shares of the company's stock worth $621,000 after buying an additional 317 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of the business's stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Trading Down 0.2%

Shares of LLY opened at $754.90 on Monday. The business's 50-day moving average price is $741.03 and its 200-day moving average price is $775.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $942.35. The stock has a market cap of $714.48 billion, a PE ratio of 49.34, a P/E/G ratio of 1.05 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the prior year, the business posted $3.92 earnings per share. The company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were given a dividend of $1.50 per share. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio is currently 39.22%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. HSBC upgraded Eli Lilly and Company from a "reduce" rating to a "hold" rating and boosted their price objective for the company from $675.00 to $700.00 in a research note on Wednesday, August 27th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Morgan Stanley restated an "overweight" rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Finally, Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $941.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.